Fundraising Fox
GT Biopharma
NASDAQ: GTBPSan Francisco, US · Delaware corporation
Find your way into GT Biopharma
Sign up to see every warm intro you have to GT Biopharma
- Paths you didn't know you had: your email and LinkedIn already hold routes to the GT Biopharma team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
GT Biopharma is a clinical-stage immuno-oncology company developing targeted cancer immunotherapies using proprietary NK cell engager technology. The company focuses on creating therapeutic agents that simultaneously engage natural killer cells and cancer cells to facilitate selective cancer cell elimination.
Founders & leadership
MB
Michael BreenExecutive
AU
Alan UrbanExecutive
AC
Anthony CataldoExecutive
SW
Steven WeldonExecutive
DS
David SaloffResigned on July 25, 2014
KE
Kenneth EatonExecutive
Board
BW
Bruce WendelBoard director
CC
Charles CasamentoBoard director
RS
Rajesh ShrotriyaBoard director
AD
Anshuman DubeResigned on July 25, 2014
HK
Hilary KramerBoard director
DC
David C. Mun-GavinBoard director
Reported raises · per SEC filings
Form D private placements$41.3M disclosed across 10 of 12 rounds · 1900–2026
▶$7.8MraisedSep 2026 · 9 investors · BiotechnologyRule 506(b)
▶$7.8MraisedSep 2026 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael BreenExecutive Officer, Director
- Alan UrbanExecutive Officer
- Charles J. CasamentoDirector
- Hilary KramerDirector
- David C. Mun-GavinDirector
- Offering amount
- $39M
- Amount sold
- $7.8M
- First sale
- Sep 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$20MofferedMay 2025 · 2 investors · BiotechnologyRule 506(b)
▶$20MofferedMay 2025 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael BreenExecutive Officer, Director
- Alan UrbanExecutive Officer
- Hilary KramerDirector
- Charles CasamentoDirector
- Andrew RitterDirector
- Offering amount
- $20M
- First sale
- May 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6MraisedMay 2025 · 9 investors · BiotechnologyRule 506(b)
▶$6MraisedMay 2025 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Charles CasamentoDirector
- Alan UrbanExecutive Officer
- Hilary KramerDirector
- Michael BreenExecutive Officer
- Andrew RitterDirector
- Offering amount
- $6M
- Amount sold
- $6M
- First sale
- May 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.3MraisedMar 2025 · 6 investors · BiotechnologyRule 506(b)
▶$1.3MraisedMar 2025 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Bruce WendelDirector
- Charles CasamentoDirector
- Michael BreenExecutive Officer, Director
- Rajesh ShrotriyaDirector
- Alan UrbanExecutive Officer
- Offering amount
- $1.3M
- Amount sold
- $1.3M
- Sales commissions
- $70K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Feb 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.6MraisedJul 2020 · 18 investors · BiotechnologyRule 506(b)
▶$5.6MraisedJul 2020 · 18 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Steven WeldonDirector
- Anthony CataldoDirector, Executive Officer
- Amount sold
- $5.6M
- Proceeds to insiders
- $250K
- First sale
- Apr 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.1MraisedAug 2018 · 13 investors · BiotechnologyRule 506(b)
▶$5.1MraisedAug 2018 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kathleen Clarence-SmithDirector
- Steven WeldonDirector, Executive Officer
- Anthony J. CataldoDirector
- Jon BonfiglioDirector
- Raymond UrbanskiExecutive Officer
- Peter KienerDirector
- Geoffrey B. DavisDirector
- Offering amount
- $5.1M
- Amount sold
- $5.1M
- First sale
- Aug 2018
- Incorporated
- Corporation, Florida
- Federal exemptions
- 06b
▶$7.1MraisedFeb 2018 · 14 investors · BiotechnologyRule 506(b)
▶$7.1MraisedFeb 2018 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Geoffrey B. DavisDirector
- Kathleen Clarence-SmithDirector, Executive Officer
- Anthony J. CataldoDirector
- Steven WeldonDirector, Executive Officer
- Offering amount
- $7.1M
- Amount sold
- $7.1M
- First sale
- Jan 2018
- Incorporated
- Corporation, Florida
- Federal exemptions
- 06b
▶$4.5MraisedSep 2017 · 9 investors · BiotechnologyRule 506(b)
▶$4.5MraisedSep 2017 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Anthony CataldoExecutive Officer, Director
- Steven WeldonExecutive Officer, Director
- Kathleen Clarence-SmithExecutive Officer, Director
- Offering amount
- $4.5M
- Amount sold
- $4.5M
- Minimum investment
- $1K
- Proceeds to insiders
- $450K
- First sale
- Aug 2016
- Incorporated
- Corporation, Florida
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$13.3Mvaluation at IPOFeb 2025 · $2.38/share · S-1/A
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Related companies · 8
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Seeking AlphaSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
NasdaqNasdaq operates a technology infrastructure platform for financial markets across three business segments: Capital Access Platforms (which includes listing services, indices, and analytics tools), Financial Technology (comprising compliance, regulatory, and capital markets software), and Market Services (equities and derivatives trading operations). The company serves financial institutions, listed companies, investment managers, and regulatory agencies globally.
StockTwitsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
TradingViewTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
Simply Wall StSimply Wall St is an investment platform that provides financial data visualization and analysis tools for individual investors. The platform serves long-term investors globally by simplifying complex market information into visual and narrative formats to make stock investing more accessible.
PublicPublic is a trading platform that allows users to buy and sell cryptocurrencies including Bitcoin, Ethereum, and memecoins through accounts managed by Zero Hash LLC, a New York State-licensed virtual currency business.
PerplexityAn AI-powered answer engine providing accurate, trusted, and real-time answers to questions.
Companies working in the same space as GT Biopharma.
Frequently asked questions
- What does GT Biopharma do?
- GT Biopharma is a clinical-stage immuno-oncology company developing targeted cancer immunotherapies using proprietary NK cell engager technology. The company focuses on creating therapeutic agents that simultaneously engage natural killer cells and cancer cells to facilitate selective cancer cell elimination.
- How much funding has GT Biopharma raised?
- GT Biopharma has disclosed $41.3M raised across 10 of its 12 known rounds.
- Where is GT Biopharma headquartered?
- GT Biopharma is headquartered in San Francisco, US.